Jove
Visualize
お問い合わせ
JoVE
x logofacebook logolinkedin logoyoutube logo
JoVEについて
概要リーダーシップブログJoVEヘルプセンター
著者向け
出版プロセス編集委員会範囲と方針査読よくある質問投稿
図書館員向け
推薦の声購読アクセスリソース図書館諮問委員会よくある質問
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experimentsアーカイブ
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教員リソースセンター教員サイト
利用規約
プライバシーポリシー
ポリシー

関連する概念動画

Atherosclerosis III: Management01:26

Atherosclerosis III: Management

33
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
33
Lipid-Lowering Drugs: Statins and Miscellaneous Agents01:20

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

865
Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
865
Coronary Artery Disease IV: Preventive Measures01:26

Coronary Artery Disease IV: Preventive Measures

32
Effective preventive measures for coronary artery disease (CAD) focus on controlling modifiable risk factors, including cholesterol abnormalities and lifestyle changes.Cholesterol ManagementFirst, the Mediterranean diet and the American Heart Association advocate for maintaining low-density lipoprotein (LDL) cholesterol levels below 100 mg/dL, with a more stringent recommendation of below 70 mg/dL for individuals at high risk. LDL cholesterol, often termed "bad cholesterol," can lead to the...
32
Hypertension IV: Drug Therapy and Lifestyle Modifications01:28

Hypertension IV: Drug Therapy and Lifestyle Modifications

37
Multiple classes of antihypertensive medications are employed in treating hypertension. The most commonly recommended first-line treatments include:Thiazide Diuretics, such as chlorthalidone, increase sodium and water excretion from the body, reducing blood volume and blood pressure.Angiotensin-converting enzyme inhibitors, like lisinopril, block the conversion of angiotensin I to II, a potent vasoconstrictor lowering blood pressure.Angiotensin II Receptor Blockers (ARBs) prevent angiotensin II...
37
Atherosclerosis IV: Nursing Management01:23

Atherosclerosis IV: Nursing Management

50
Nursing management for a patient with arteriosclerosis involves a comprehensive approach focusing on lifestyle modification, disease monitoring, education, and symptomatic care. Here is an overview of effective nursing strategies:Assessment and Monitoring: Initial and ongoing assessments are crucial. Nurses must document the patient's medical history, including any hypertension, diabetes, hyperlipidemia, and other cardiovascular diseases. Assessments also cover family history and lifestyle...
50
Coronary Artery Disease V: Interprofessional Care01:27

Coronary Artery Disease V: Interprofessional Care

30
Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
30
このページは機械翻訳されています。他のページは英語で表示される場合があります。View in English
  1. ホーム
  2. 研究分野
  3. 生物医学と臨床科学
  4. 心血管医学と血液学
  5. 心臓病 (心血管疾患を含む)
  6. 高リスクascvdの初次および二次予防のためのacc/ahaガイドラインに従ってリピッド低下療法のための現実世界の処方:リピッド低下療法のための現実世界の処方

高リスクASCVDの初次および二次予防のためのACC/AHAガイドラインに従ってリピッド低下療法のための現実世界の処方:リピッド低下療法のための現実世界の処方

Jonathan Arnold1, Deeksha Acharya2, Hetal Boricha2

  • 1Department of Medicine, University of Pittsburgh School of Medicine, USA.

American journal of preventive cardiology
|September 2, 2025

関連する実験動画

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles
09:15

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles

Published on: November 10, 2017

14.7K
Hydra, a Computer-Based Platform for Aiding Clinicians in Cardiovascular Analysis and Diagnosis
07:51

Hydra, a Computer-Based Platform for Aiding Clinicians in Cardiovascular Analysis and Diagnosis

Published on: September 26, 2018

7.7K
Acetylcholine Re-Challenge After Intracoronary Nitroglycerine Administration
07:59

Acetylcholine Re-Challenge After Intracoronary Nitroglycerine Administration

Published on: April 4, 2022

1.4K

PubMed で要約を見る

まとめ
この要約は機械生成です。

脂質低下療法 (LLT) は,動脈硬化性心血管疾患 (ASCVD) の予防に不可欠です. しかし,実際のデータでは,多くの患者がガイドラインで推奨されている高強度スタチン療法を受けていないことが示され,ASCVDのリスク軽減戦略の改善の必要性を示しています.

科学分野:

  • 心臓病科
  • 予防医学
  • 医療サービス研究

背景:

  • 脂質低下療法 (LLT) は,動脈硬化性心血管疾患 (ASCVD) の予防に不可欠である.
  • ガイドラインは,二次的および高リスクのASCVDの予防のためにスタチン治療を推奨しています.
  • 以前の研究では,特定の集団と環境において,指針の順守が最適でないことが示された.

研究 の 目的:

  • リアルな世界でのLLTの処方パターンを特徴づけるため
  • 多様な患者集団と複数の米国保健システムにおけるガイドラインの遵守を評価する.

主な方法:

  • PaTH臨床研究ネットワークからの電子医療記録の横断分析
  • 3つのコホートを含む:ASCVD,ASCVDのない糖尿病 (DM),高LDL-C (>190 mg/dL).
  • 各コホートおよび医療システム全体で記録された患者の特徴,ケアパターン,脂質レベル,およびLLTの評価.

主要な成果:

  • 240,625人のASCVD,113,662人のDM,および11,276人の高LDL-C患者の分析.
  • LDL-Cの目標値の低達成率 (<70 mg/ dL):ASCVDでは37%,DMでは27%.
  • 高強度スタチンの非最適使用:ASCVDでは34%,DMでは19%,高LDL-C群では16%.
キーワード:
心血管疾患薬の処方薬物使用

関連する実験動画

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles
09:15

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles

Published on: November 10, 2017

14.7K
Hydra, a Computer-Based Platform for Aiding Clinicians in Cardiovascular Analysis and Diagnosis
07:51

Hydra, a Computer-Based Platform for Aiding Clinicians in Cardiovascular Analysis and Diagnosis

Published on: September 26, 2018

7.7K
Acetylcholine Re-Challenge After Intracoronary Nitroglycerine Administration
07:59

Acetylcholine Re-Challenge After Intracoronary Nitroglycerine Administration

Published on: April 4, 2022

1.4K
  • 医療制度の間で観察されたLLTの処方パターンの有意な変動.
  • 結論:

    • ASCVD予防の基準を満たすほとんどの患者は,記録された高強度スタチン療法を受けていません.
    • 患者の有意な割合は,推奨されるLDL- C目標値を達成しません.
    • 医療システムにおける介護の変動は,ガイドラインの遵守を改善し,ASCVDのリスクを減らす機会を強調しています.
    ハイドロキシメチルグルタリル-コア還元酵素阻害剤
    高コレステロール血症
    LDL コレステロール
    脂質低下療法
    実践パターン
    主要な予防
    現実世界の証拠
    二次予防
    スタチン